Pushpa Itagi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Pushpa Itagi has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Caleb Hsieh
Human Biology Division, Fred Hutchinson Cancer Center, Seattle, USA
10 shared publications - Colm Morrissey
Department of Urology, University of Washington, Seattle, Washington
10 shared publications - Erolcan Sayar
Human Biology Division, Fred Hutchinson Cancer Center, Seattle, USA
10 shared publications - Gavin Ha
Division of Human Biology, Fred Hutchinson Cancer Center
10 shared publications - Ilsa Coleman
Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington
10 shared publications - Michael C. Haffner
Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington, USA
10 shared publications
Latest Publications
- Open Access
Deep learning-based non-invasive profiling of tumor transcriptomes from cell-free DNA for precision oncology
Circulating tumor DNA (ctDNA) profiling from liquid biopsies is increasingly adopted as a minimally invasive solution for clinical cancer diagnostic applications. Current methods for inferring gene expression from ctDNA require specialized assays or ultra-deep, targeted sequencing, which preclude transcriptome-wide profiling at single-gene resolution. Herein we jointly introduce Triton, a tool for comprehensive fragmentomic and nucleosome profiling of cell-free DNA (cfDNA), and Proteus, a multi-modal deep learning framework for predicting single gene expression, using standard depth (∼30-120x) whole genome sequencing of cfDNA. By synthesizing fragmentation and inferred nucleosome positioning patterns in the promoter and gene body from Triton, Proteus reproduced expression profiles using pure ctDNA from patient-derived xenografts (PDX) with an accuracy similar to RNA-Seq technical replicates. Applying Proteus to cfDNA from four patient cohorts with matched tumor RNA-Seq, we show that the model accurately predicted the expression of specific prognostic and phenotype markers and therapeutic targets. As an analog to RNA-Seq, we further confirmed the immediate applicability of Proteus to existing tools through accurate prediction of gene pathway enrichment scores. Our results demonstrate the potential clinical utility of Triton and Proteus as non-invasive tools for precision oncology applications such as cancer monitoring and therapeutic guidance. Subjects: Circulating tumor DNA, liquid biopsies, patient-derived xenografts, whole genome sequencing, deep learning, convolutional neural network, gene expression
Open AccessDeep learning-based non-invasive profiling of tumor transcriptomes from cell-free DNA for precision oncology
Circulating tumor DNA (ctDNA) profiling from liquid biopsies is increasingly adopted as a minimally invasive solution for clinical cancer diagnostic applications. Current methods for inferring gene expression from ctDNA require specialized assays or ultra-deep, targeted sequencing, which preclude transcriptome-wide profiling at single-gene resolution. Herein we jointly introduce Triton, a tool for comprehensive fragmentomic and nucleosome profiling of cell-free DNA (cfDNA), and Proteus, a multi-modal deep learning framework for predicting single gene expression, using standard depth (∼30-120x) whole genome sequencing of cfDNA. By synthesizing fragmentation and inferred nucleosome positioning patterns in the promoter and gene body from Triton, Proteus reproduced expression profiles using pure ctDNA from patient-derived xenografts (PDX) with an accuracy similar to RNA-Seq technical replicates. Applying Proteus to cfDNA from four patient cohorts with matched tumor RNA-Seq, we show that the model accurately predicted the expression of specific prognostic and phenotype markers and therapeutic targets. As an analog to RNA-Seq, we further confirmed the immediate applicability of Proteus to existing tools through accurate prediction of gene pathway enrichment scores. Our results demonstrate the potential clinical utility of Triton and Proteus as non-invasive tools for precision oncology applications such as cancer monitoring and therapeutic guidance. Subjects: Circulating tumor DNA, liquid biopsies, patient-derived xenografts, whole genome sequencing, deep learning, convolutional neural network, gene expression
- Open Access
- 25 August 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
A and B, Box plots indicating the relationship between HER2 score with protein expression of key cell surface antigens as measured by IHC in (A) prostate cancer and (B) urothelial cancer.
- 25 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
A and B, Box plots indicating the relationship between HER2 score with protein expression of key cell surface antigens as measured by IHC in (A) prostate cancer and (B) urothelial cancer.
- Open Access
- 25 August 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Estimated probabilities of HER2 expression conditional on an index sample
- 25 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Estimated probabilities of HER2 expression conditional on an index sample
- Open Access
- 25 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Prostate cancer cohort supplemental table
- 25 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Prostate cancer cohort supplemental table
- Open Access
- 25 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Figure S1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
- 25 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Figure S1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
- Open Access
- 25 August 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
A and B, Representative micrographs of HER2 IHC staining in prostate cancer (A) and urothelial cancer (B) autopsy specimens. C, Number of patients with at least one tumor with the indicated HER2 IHC score, color coded by cancer type. D, Number of tumors across all patients with the indicated HER2 IHC score, color coded by cancer type. E and F, Percent of tumors expressing the indicated level of HER2 staining by IHC according to the tumor site sampled in prostate (E) and urothelial (F) cancer cohorts. Anatomic sites with only one representative tumor were excluded. PC, prostate cancer; UC, urothelial carcinoma.
- 25 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
A and B, Representative micrographs of HER2 IHC staining in prostate cancer (A) and urothelial cancer (B) autopsy specimens. C, Number of patients with at least one tumor with the indicated HER2 IHC score, color coded by cancer type. D, Number of tumors across all patients with the indicated HER2 IHC score, color coded by cancer type. E and F, Percent of tumors expressing the indicated level of HER2 staining by IHC according to the tumor site sampled in prostate (E) and urothelial (F) cancer cohorts. Anatomic sites with only one representative tumor were excluded. PC, prostate cancer; UC, urothelial carcinoma.
- Open Access
- 25 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Figure S2 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
- 25 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Figure S2 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
- Open Access
- 25 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Supplementary Table 2 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
- 25 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Supplementary Table 2 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
- Open Access
- 25 August 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
A and B, Mosaic plots indicating the relationship between ERBB2 genomic status as assessed by unadjusted copy number and HER2 IHC in (A) prostate and (B) urothelial cancers. C and D, Box plots indicating the relationship between HER2 RNA expression with (C) prostate and (D) urothelial cancers. PC, prostate cancer; UC, urothelial carcinoma.
- 25 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
A and B, Mosaic plots indicating the relationship between ERBB2 genomic status as assessed by unadjusted copy number and HER2 IHC in (A) prostate and (B) urothelial cancers. C and D, Box plots indicating the relationship between HER2 RNA expression with (C) prostate and (D) urothelial cancers. PC, prostate cancer; UC, urothelial carcinoma.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 5 (8) , 1419-1428
Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
HER2 is an oncogenic driver in multiple cancers and a predictive biomarker for HER2-targeted therapies. Although HER2-directed therapies like fam-trastuzumab deruxtecan are approved for HER2-positive breast and other solid tumors, the landscape of HER2 expression in advanced prostate cancer and urothelial carcinoma remains inadequately characterized. We evaluated HER2 protein expression in metastatic prostate cancer and urothelial carcinoma using a validated IHC assay on tissue microarrays constructed from the University of Washington Tissue Acquisition Necropsy Program. HER2 expression was scored using standardized gastric cancer criteria. Genomic analysis of ERBB2 alterations was conducted on a subset of samples. HER2 expression heterogeneity and its relationship with other surface markers were also evaluated. In the prostate cancer cohort (n = 52 patients, 1–19 tumors per patient), HER2 expression was low, with no 3+ expression observed and only five (10%) patients exhibiting 2+ expression. Low-level ERBB2 copy-number gains were observed in some tumors but did not correlate with HER2 protein expression (P = 0.2). In urothelial carcinoma (n = 20, 2–6 tumors per patient), HER2 expression was more frequent, with ≥2+ expression observed in six (30%) cases and 3+ expression observed in three (15%) cases in at least one tumor. Urothelial carcinoma samples showed less heterogeneity, with more consistent expression across metastases. HER2 overexpression is rare and heterogeneous in metastatic prostate cancer, limiting its utility as a therapeutic target. HER2 expression is more prevalent and uniform in urothelial carcinoma. These findings underscore the importance of comprehensive HER2 assessment in advanced urothelial carcinoma and suggest that success of HER2-directed therapies in prostate cancer will require careful case selection. Significance: This study demonstrates that HER2 is rarely overexpressed in metastatic prostate cancer but is more common and consistent in urothelial carcinoma. These findings highlight the need for HER2 testing in urothelial cancer and suggest that HER2-targeted therapies in prostate cancer will require careful patient selection.
- 1 August 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 5 (8) , 1419-1428
Open AccessPatterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
HER2 is an oncogenic driver in multiple cancers and a predictive biomarker for HER2-targeted therapies. Although HER2-directed therapies like fam-trastuzumab deruxtecan are approved for HER2-positive breast and other solid tumors, the landscape of HER2 expression in advanced prostate cancer and urothelial carcinoma remains inadequately characterized. We evaluated HER2 protein expression in metastatic prostate cancer and urothelial carcinoma using a validated IHC assay on tissue microarrays constructed from the University of Washington Tissue Acquisition Necropsy Program. HER2 expression was scored using standardized gastric cancer criteria. Genomic analysis of ERBB2 alterations was conducted on a subset of samples. HER2 expression heterogeneity and its relationship with other surface markers were also evaluated. In the prostate cancer cohort (n = 52 patients, 1–19 tumors per patient), HER2 expression was low, with no 3+ expression observed and only five (10%) patients exhibiting 2+ expression. Low-level ERBB2 copy-number gains were observed in some tumors but did not correlate with HER2 protein expression (P = 0.2). In urothelial carcinoma (n = 20, 2–6 tumors per patient), HER2 expression was more frequent, with ≥2+ expression observed in six (30%) cases and 3+ expression observed in three (15%) cases in at least one tumor. Urothelial carcinoma samples showed less heterogeneity, with more consistent expression across metastases. HER2 overexpression is rare and heterogeneous in metastatic prostate cancer, limiting its utility as a therapeutic target. HER2 expression is more prevalent and uniform in urothelial carcinoma. These findings underscore the importance of comprehensive HER2 assessment in advanced urothelial carcinoma and suggest that success of HER2-directed therapies in prostate cancer will require careful case selection. Significance: This study demonstrates that HER2 is rarely overexpressed in metastatic prostate cancer but is more common and consistent in urothelial carcinoma. These findings highlight the need for HER2 testing in urothelial cancer and suggest that HER2-targeted therapies in prostate cancer will require careful patient selection.